Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) has terminated Valeant Pharmaceuticals’ (TSX: VRX) right to develop and commercialize brodalumab in Europe, according to a statement.
It follows an announcement earlier that exclusive rights to develop and commercialize the IL-17 receptor monoclonal antibody have now been granted to LEO Pharma.
Brodalumab is currently under regulatory review for the treatment of moderate-to-severe plaque psoriasis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze